Could Younger Blood Hold Clues to Slowing Alzheimer's? What Scientists Just Discovered

Scientists have discovered that the blood circulating in our bodies may play a crucial role in how Alzheimer's disease develops and progresses. In groundbreaking research using mice, blood from younger animals appeared to protect against Alzheimer's-related brain damage, while blood from older animals actually sped up the disease process.

How Did Scientists Test Young vs. Old Blood?

Researchers from the Instituto Latinoamericano de Salud Cerebral at Universidad Adolfo Ibáñez, working with collaborators from multiple institutions, conducted a 30-week experiment using Tg2576 transgenic mice—a widely used model for Alzheimer's research. The mice received weekly blood infusions from either young or aged donor mice to see how different blood components might affect brain health and memory.

The team measured cognitive performance using specialized memory tests and analyzed amyloid plaque buildup—the toxic protein clumps that are a hallmark of Alzheimer's disease. They also conducted detailed protein analysis of brain tissue, identifying more than 250 proteins whose activity levels had changed based on the type of blood the mice received.

What Makes Blood So Important for Brain Health?

Alzheimer's disease is marked by the buildup of beta-amyloid protein in the brain, which forms plaques that interfere with communication between neurons. While these proteins are produced in the brain, recent research has shown they can also be detected in the bloodstream, raising questions about whether blood-based factors might influence disease progression.

The study revealed that many of the affected proteins are involved in critical brain functions:

• Synaptic Function: Proteins that help brain cells communicate with each other showed significant changes
• Endocannabinoid Signaling: Systems involved in regulating mood, memory, and pain perception were affected
• Calcium Channel Regulation: Mechanisms that control how brain cells process and store information were altered

"This collaborative work between various institutions reinforces the importance of understanding how systemic factors condition the brain environment and directly impact mechanisms that promote disease progression," explained Dr. Claudia Durán-Aniotz of the Instituto Latinoamericano de Salud Cerebral at Universidad Adolfo Ibáñez.

What Does This Mean for Future Alzheimer's Treatments?

The findings add to growing evidence that circulating factors in the blood can directly affect neurodegenerative diseases like Alzheimer's. By demonstrating that peripheral signals from aged blood can influence central brain processes, the research opens new opportunities for studying therapeutic targets aimed at the blood-brain connection.

The technical complexity of analyzing blood proteins presented significant challenges. "Within this study, we conducted a large-scale proteomic analysis that allowed us to generate excellent quality data in this complex matrix like plasma, a technical challenge for any proteomics laboratory," noted Mauricio Hernández, a proteomics specialist at MELISA Institute.

Future research will focus on identifying the specific blood-based factors involved and determining whether they can be safely targeted in humans. This could potentially lead to new treatment strategies that work through the bloodstream rather than trying to directly target the brain—a notoriously difficult organ to reach with medications.

"It is a pleasure to contribute our proteomic capabilities to support innovative research initiatives like this study, which allow us to advance the knowledge and development of new therapies for neurodegenerative diseases, which are currently a global health problem," said Dr. Elard Koch, Chairman of MELISA Institute.